Home Compare BMY vs ILMN
Stock Comparison · Structural lead, mixed market

Bristol-Myers Squibb Company vs Illumina: Which Stock Looks Stronger in 2026?

Bristol-Myers Squibb Company holds the cleaner structural position, with the lead spread across stability and profitability. Illumina still has the edge on profitability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.

Updated 2026-05-17

Stability drives the lead, while growth keeps the result from looking one-sided.

Trajectory Similarity
0.67
Moderately similar
Peer-set rank: #9
within Bristol-Myers Squibb Company's functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The strongest overlap appears in recent revenue growth and capital structure.

Similarity drivers
recent revenue growthcapital structure
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
BMY
Bristol-Myers Squibb Company
57
Peer-Score
Signal qualitylow
Peer basis: Russell 1000
vs
ILMN
Illumina, Inc.
51
Peer-Score
Signal qualityMedium
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: BMY vs ILMN Profitability 45 75 Stability 59 20 Valuation 87 60 Growth 27 30 BMY ILMN
Gap Ranking
#1 Stability +39
#2 Profitability +30
#3 Valuation +27
#4 Growth +3
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BMY and ILMN Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BMYILMN Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against Illumina, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Entry today — historical context

Where BMY and ILMN each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY BMY Neutral · near norm 0th 50th 100th 18 pct gap ILMN Neutral · above norm 0th 50th 100th 69th 51st
Today ILMN sits in the upper-middle of its own 5-year history (51st percentile), while BMY sits higher in its own history (69th). Within each stock's own 5-year context, ILMN is at a historically more favourable entry position than BMY. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Stability
On stability, Bristol-Myers Squibb Company is positioned higher in the group, while Illumina, Inc. is closer to the middle.
Profitability
Both rank well on profitability, but Illumina, Inc. still holds a clear edge.
Stability — Dominant Gap
BMY
59
ILMN
20
Gap+39in favour of BMY

The stability gap is wide, with the stronger side looking materially steadier through time.

What keeps the gap from being one-sided

Capital efficiency also runs the other way, with a 7.9-point ROIC edge acting as a real counterforce.

What this means for the comparison

Stability settles the comparison, while pricing and profitability keep the broader setup from looking fully aligned.

Explore full peer positioning in AssetNext

Break down the BMY vs ILMN comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how BMY and ILMN each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.